间充质干细胞微泡——ARDS治疗的新希望  

Microvesicles derived from mesenchymal stem cells： new hope of the treatment for ARDS

作　　者：陈齐红[1] 郑瑞强[1] 汪华玲[2] Chen Qihong Zheng Ruiqiang Wang Hualing(Department of Critical Care Medicine, Subei People＇ Hospital, Yangzhou 225001, Jiangsu, China Department of Cardiology, Subei People＇ Hospital, Yangzhou 225001, Jiangsu, China)

机构地区：[1]江苏省苏北人民医院重症医学科,江苏扬州225001 [2]江苏省苏北人民医院心内科,江苏扬州225001

出　　处：《中华危重病急救医学》2017年第9期774-777,共4页Chinese Critical Care Medicine

基　　金：国家自然科学基金（81670065）;江苏省社会发展项目（BE2017691）

摘　　要：急性呼吸窘迫综合征（ARDS）是严重威胁人类健康的常见危重症,病死率高达30%~40%,目前临床尚无有效的治疗手段.间充质干细胞（MSC）来源微泡（MSC-MVs）是MSC分泌的具有异质性的亚细胞结构群,在组织器官损伤修复中起到了重要作用.近年来研究表明,MSC-MVs能替代MSC进行细胞治疗,可减轻ARDS肺损伤,促进组织修复,因此MSC-MVs可能为ARDS治疗带来新的希望.Acute respiratory distress syndrome （ARDS） is a serious state threaten human health with a high mortality about 30%-40%. At present, there is no effective treatment for ARDS. Microvesicles derived from mesenchymal stem cells （MSC-MVs） have a heterogeneous subcellular structure secreted by MSCs. It plays an important role in the repair of tissue and organ damage.Recent studies have shown that MSC-MVs, played an important role in repairing lung injury, may replace MSC for cell therapy. Therefore MSC-MVs may bring new hope for ARDS treatment.

关 键 词：间充质干细胞 微泡 急性呼吸窘迫综合征 

分 类 号：R563.8[医药卫生—呼吸系统]